Compare · BLLN vs ELV
BLLN vs ELV
Side-by-side comparison of BillionToOne Inc. (BLLN) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLLN and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $86.08B, about 18.4x BLLN ($4.68B).
- Over the past year, BLLN is down 9.7% and ELV is up 26.0% - ELV leads by 35.7 points.
- BLLN has been more active in the news (9 items in the past 4 weeks vs 2 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 9 for BLLN).
PerformanceBLLN-9.70%ELV+26.27%
2025-11-06+0.00%2026-09-09
- Company
- BillionToOne Inc.
- Elevance Health Inc.
- Price
- $99.08+0.03%
- $397.15-1.22%
- Market cap
- $4.68B
- $86.08B
- 1M return
- +0.57%
- -0.07%
- 1Y return
- -9.70%
- +26.01%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 9
- 2
- Recent ratings
- 9
- 23
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest BLLN
- Chief Technology Officer Tsao David converted options into 20,000 shares and gifted 20,000 shares (SEC Form 4)
- SEC Form 144 filed by BillionToOne Inc.
- BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Canaccord Genuity initiated coverage on BillionToOne with a new price target
- BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
- Director Kolluri Krishna Kittu disposed of 484,442 shares and acquired 78,244 shares (SEC Form 4)
- SVP of Laboratory Operations Ten Bosch John Roderick sold $141,700 worth of shares (1,417 units at $100.00) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 26,467 units (SEC Form 4)
- Chief Technology Officer Tsao David exercised 10,000 shares at a strike of $2.80 and sold $1,000,000 worth of shares (10,000 units at $100.00) as part of a pre-agreed trading plan (SEC Form 4)
- Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
- SVP of Laboratory Operations Ten Bosch John Roderick sold $131,583 worth of shares (1,417 units at $92.86) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 27,884 units (SEC Form 4)
Latest ELV
- EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 349 shares, decreasing direct ownership by 5% to 7,230 units (SEC Form 4)
- EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 144 shares, decreasing direct ownership by 2% to 6,530 units (SEC Form 4)
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act